8-K: Amwell Co-Founder Roy Schoenberg Transitions to Executive Vice Chairman Role

Amwell's co-founder, Roy Schoenberg, is stepping down as co-CEO to become Executive Vice Chairman, while Ido Schoenberg will assume the role of sole CEO.

Summary

• Roy Schoenberg, co-founder of Amwell, has resigned as President and co-Chief Executive Officer, effective June 13, 2024.
• He will transition to the role of Executive Vice Chairman of the Board.
• Ido Schoenberg will become the sole Chief Executive Officer of Amwell.
• Roy Schoenberg's resignation was related to his new appointment and not due to any disagreements with the company.
• As Executive Vice Chairman, Roy Schoenberg will receive an annual base salary of $325,000, which may increase to maintain 50% of the CEO's salary.
• He will also be eligible for an annual target bonus of 150% of his base salary.
• Roy Schoenberg will receive $1,950,000 in transition benefits, which satisfies any potential severance obligations and accelerates all outstanding equity awards, except for Performance Stock Units (PSUs).
• If his employment as Executive Vice Chairman is involuntarily terminated, he will receive accrued compensation, any earned but unpaid bonuses, full acceleration of equity awards (excluding PSUs), and COBRA benefits for 36 months.
• He will not receive severance payments if terminated for any other reason.
• The agreements include customary confidentiality, intellectual property assignment, non-competition, and non-solicitation restrictions for 24 months post-termination.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive, reflecting a planned leadership transition and a strategic shift towards operational efficiency. While there are no explicit negative statements, the change in leadership and focus could introduce some uncertainty.

Positives

• Roy Schoenberg's transition to Executive Vice Chairman allows him to continue contributing to the company's strategic direction.
• The transition is described as a natural evolution for the company.
• The company is shifting focus to operational efficiency and profitable growth.
• The company is maintaining its dedication to enabling clients' aspirations.

Negatives

• The company is undergoing a significant leadership change.
• Roy Schoenberg is no longer in a day-to-day operational role.
• The company is moving away from a period of intense R&D investment.

Risks

• The leadership transition could create uncertainty within the company.
• The shift in focus from R&D to operations may impact innovation.
• The company's ability to achieve profitable growth remains to be seen.
• There is a risk that the company may not be able to maintain its dedication to enabling clients' aspirations.

Future Outlook

The company is shifting from a period of intense R&D investment to an operational focus aimed at achieving greater efficiencies, optimizing cash flow, and delivering profitable growth while maintaining its dedication to enabling its clients' aspirations.

Management Comments

• Roy Schoenberg stated, 'The time is now to take the next step in our mission. Our unique opportunity to realize the immense value in new Amwell technology while achieving critical operational and clinical goals is both timely and exciting. I am confident in our talented leadership team and will continue to support them in our journey to digitally reimagine healthcare.'
• Ido Schoenberg said, 'This transition represents a natural evolution for our company as we shift from a period of intense R&D investment to an operational focus aimed at achieving greater efficiencies, optimizing cash flow and delivering profitable growth while maintaining our dedication to enabling our clients aspirations.'

Industry Context

This announcement reflects a broader trend in the digital health industry where companies are focusing on operational efficiency and profitability after a period of rapid growth and investment in technology. The leadership change suggests a strategic shift towards a more mature phase of business development.

Comparison to Industry Standards

• The transition of a co-founder to an executive chairman role is not uncommon in the tech industry, often signaling a shift in strategic focus.
• The compensation package for the Executive Vice Chairman, including base salary, bonus, and transition benefits, appears to be in line with industry standards for similar roles.
• The non-compete and non-solicitation clauses are standard practice in executive employment agreements to protect company interests.
• The focus on operational efficiency and profitable growth is a common theme among publicly traded digital health companies, such as Teladoc and Livongo, as they seek to demonstrate sustainable business models to investors.

Management Changes

Stakeholder Impact

• Shareholders may react to the leadership change and strategic shift.
• Employees may experience changes in their roles and responsibilities.
• Customers may see changes in the company's products and services.
• Suppliers may be affected by the company's focus on operational efficiency.
• Creditors may be impacted by the company's focus on optimizing cash flow.

Next Steps

• Ido Schoenberg will assume the role of sole CEO.
• The company will focus on achieving greater efficiencies, optimizing cash flow, and delivering profitable growth.
• The company will continue to develop and implement the Amwell Converge platform.

Key Dates

Keywords

Executive Transition, Leadership Change, Digital Healthcare, Telehealth, Corporate Governance, Executive Compensation, Operational Efficiency, Profitable Growth, Hybrid Care, Board of Directors